KR920702425A - Cdr 이식된 항-cea 항체 및 그의 제조 - Google Patents

Cdr 이식된 항-cea 항체 및 그의 제조

Info

Publication number
KR920702425A
KR920702425A KR1019920700490A KR920700490A KR920702425A KR 920702425 A KR920702425 A KR 920702425A KR 1019920700490 A KR1019920700490 A KR 1019920700490A KR 920700490 A KR920700490 A KR 920700490A KR 920702425 A KR920702425 A KR 920702425A
Authority
KR
South Korea
Prior art keywords
ham
cdr
chain
derived
variable region
Prior art date
Application number
KR1019920700490A
Other languages
English (en)
Inventor
존 로버트 어데어
마아크 윌리엄 보드머
앤드류 마우틴
레이몬드 존 오웬스
Original Assignee
원본미기재
셀텍크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1990/002017 external-priority patent/WO1991009967A1/en
Application filed by 원본미기재, 셀텍크 리미티드 filed Critical 원본미기재
Publication of KR920702425A publication Critical patent/KR920702425A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

CDR 이식된 항 -CEA 항체 및 그의 제조
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 예상되는 아미노산 서열과 함께 cDNA클론을 서열화하여 얻은 A5B7 MAb의 처리되지 않은 가변부위를 암호화하는 DNA서열이다. 제2도는 키메라화된 H사슬 유전자의 제한과 결찰에 의한 제조의 대략적 도표이다. 제3도는 키메라화된 L사슬 유전자의 부위-직접적 돌연변이 유발, 제한 및 결찰에 의한 제조의 대략적 도표이다.

Claims (17)

  1. 암배항원에 대해 특이성이 있고 다양한 가변성 영역의 상보성 결정부위(CDR)의 적어도 한 부분은 마우스모노클로날 항체 A5B7(A5A7 MAb)에서 유도되고 HAM의 나머지 면역글로부린-유도부는 인간 면역글로부린에서 유도된 항원 결합부위를 가지는 인간형화 된 항체분자(HAM).
  2. 제1항에 있어서, 인간형화 된 키메라 항체분자임을 특징으로 하는 HAM.
  3. 제1항에 있어서, CDR-이식 인간형화된 항체임을 특징으로 하는 HAM.
  4. 제1-3항의 어느 한 항에 있어서, DNA재조합 기술에 의해 제조되는 경우 임을 특징으로 하는 HAM.
  5. 제1-4항의 어느 한 항에 있어서, 완전한 항체 분자나, 또는 Fab, Fab', (Fab')2나 Fv단편이나, 단일사슬 항체 단편을 포함함을 특징으로 하는 HMA.
  6. 제1-5항의 어느 한 항에 있어서, 효과기나 또는 보고기 분자가 거기에 부착되어 있음을 특징으로 하는 HMA.
  7. H사슬 및/또는 L사슬에 대한 LAY, POM, TUR, TEI, KOL, NEWM, REI 이나 EU가변부위 골격서열을 포함하는 제3-6항의 어느 한항에 따르는 CDR-이식 HMA.
  8. 제7항에 있어서, H사슬과 L사슬 모두에 대한 LAY가변부위 골격서열을 포함함을 특징으로 하는 CDR-이식 HAM.
  9. 제3-8항의 어느 한 항에 있어서, L사슬의 가변부위의 24-34위치(CDR1), 50-56위치(CDR2) 및 92-96위치나 또는 89-97위치(CDR3)에 A5B7 CDR을 가짐을 특징으로 하는 CDR-이식 HAM.
  10. 제3-9항의 어느 한항에 있어서, L사슬의 가변부위의 1,2 및/또는 3, 46, 47,49,60,70,84,85 및 87위치중의 하나나 그 이상의 위치, 바람직하게는 적어도 46과 47위치에 A5B7을 포함함을 특징으로 하는 CDR-이식 HAM.
  11. 제3-10항의 어느 한 항에 있어서, H사슬의 가변부위의 24-35위치나 또는 26-35위치(CDR1), 50-65위치(CDR2)및 95-100이나 94-100위치(CDR3)에 A5B7 CDR을 가짐을 특징으로 하는 CDR-이식 HAM.
  12. 제3-11항의 어느 한 항에 있어서, H사슬의 가변부위의 23 및/또는 24, 71 및/또는 48 및/또는 49,69,76 및/또는 78,80,88 및/또는 91과 6위치중의 하나나 그 이상의 위치에서 A5B7잔기를 가짐을 특징으로 하는 CDR-이식 HAM.
  13. 제8항에 있어서, L사슬의 1,2,3,4,46과 71위치와 특별히는 21,47과 73위치에서, H사슬의 1,24,48,49,72,73,76과 93과 특별히는 82b과 86위치에서 A5B7 잔기를 포함함을 특징으로 하는 CDR- 이식 HAM.
  14. 제13항에 있어서, L사슬의 24-34위치(CDR1), 50-56위치(CDR2)와, 89-97위치(CDR3)와, H사슬의 26-35위치(CDR1), 50-65위치(CDR2)와, 95-102위치(CDR3)에 A5B7을 포함함을 특징으로 하는 CDR-이식 HAM.
  15. 제약학적으로 허용가능한 부형제, 희석제나 담체와 결합되어 있는 전술한 항중의 어느 한항에 따르는 HAM을 포함하는 치료나 진단 조성물.
  16. 제15항에 따르는 치료나 진단조성물 사람에게 효과량으로 투여함을 포함하는 치료나 또는 진단 방법.
  17. 다음의 (a)∼(d)를 포함하는 제1-14항의 어느 한 항에 따르는 HAM의 제조방법. (a)가변성 영역의 CDR의 적어도 하나는 A5B7 MAb에서 유도되고 항체 사슬의 너머지 면역글로부린-유도부는 인간 면역글로부린에서 유도된 가변성 영역을 포함하는 항체의 H사슬이나 또는 L사슬을 암호화하는 DNA서열을 가지는 오페론을 발현 벡터내에서 제조; (b)가변성 영역의 CDR의 적어도 하나는 A5B7 MAb에서 유도되고 항체 사슬의 나머지 면역글로부린-유도부는 인간 면역글로부린에서 유도된 가변성 영역을 포함하는 상보성의 항체 H사슬이나 또는 L사슬을 암호화하는 DNA서열을 가지는 오페론을 발현 벡터내에서 제조; (c)숙주세포를 해당 벡터나 각각의 벡터로 형질감염시키고, (d) HAM을 제조하기 위해 형질감염된 세포주를 배양.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019920700490A 1990-07-05 1991-07-05 Cdr 이식된 항-cea 항체 및 그의 제조 KR920702425A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909014932A GB9014932D0 (en) 1990-07-05 1990-07-05 Recombinant dna product and method
GB90149329 1990-08-05
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies
GBPCT/GB90/02017WO 1990-12-21
PCT/GB1991/001108 WO1992001059A1 (en) 1990-07-05 1991-07-05 Cdr grafted anti-cea antibodies and their production

Publications (1)

Publication Number Publication Date
KR920702425A true KR920702425A (ko) 1992-09-04

Family

ID=10678718

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700490A KR920702425A (ko) 1990-07-05 1991-07-05 Cdr 이식된 항-cea 항체 및 그의 제조

Country Status (10)

Country Link
US (1) US5877293A (ko)
EP (1) EP0491031B1 (ko)
JP (1) JPH05502587A (ko)
KR (1) KR920702425A (ko)
AT (1) ATE137534T1 (ko)
AU (1) AU651984B2 (ko)
CA (1) CA2065325C (ko)
DE (1) DE69119211T2 (ko)
GB (2) GB9014932D0 (ko)
WO (1) WO1992001059A1 (ko)

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ATE217909T1 (de) * 1992-02-14 2002-06-15 Suntory Ltd Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper
GB9215540D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
GB9215541D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
GB9215550D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
DE69331735T2 (de) * 1992-12-10 2002-09-26 Celltech Therapeutics Ltd Gegen das A33 Antigen gerichtete Humanisierte Antikörper
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
WO1996002576A1 (fr) * 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
DE19518769C2 (de) * 1995-05-22 1997-04-17 Gsf Forschungszentrum Umwelt Inter-LINE-PCR
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
DK0998486T4 (da) 1997-06-13 2012-05-14 Genentech Inc Proteinoprensning ved kromatografi efterfulgt af filtrering på en ladet fase
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1056859A1 (en) * 1998-02-25 2000-12-06 The Dow Chemical Company High affinity humanized anti-cea monoclonal antibodies
GB9818915D0 (en) * 1998-08-28 1998-10-21 Ks Biomedix Ltd Antibodies
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1283214B1 (en) 2000-04-21 2007-02-14 Fuso Pharmaceutical Industries Ltd. Novel collectins
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
JP2004506695A (ja) * 2000-08-24 2004-03-04 ワシントン　デンタル　サービス う蝕の予防の免疫学的方法
PT1399483E (pt) 2001-01-05 2010-07-20 Pfizer Anticorpos contra o receptor do factor i de crescimento tipo insulina
WO2002062850A2 (en) * 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
AU2002307554A1 (en) * 2001-04-23 2002-11-05 Abgenix, Inc. Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US8361464B2 (en) * 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
DK1997512T3 (da) 2002-04-09 2014-01-27 Biogen Idec Inc Fremgangsmåder til behandling af TWEAK-relaterede tilstande
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US20040126372A1 (en) * 2002-07-19 2004-07-01 Abbott Biotechnology Ltd. Treatment of TNFalpha related disorders
CA2495121A1 (en) 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
JP4790413B2 (ja) 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE60332483D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
WO2004093893A2 (en) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
US7767641B2 (en) * 2003-04-24 2010-08-03 Yale University Regulator of endothelial cell function and vessel remodeling
JP4804357B2 (ja) * 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
RU2401277C2 (ru) 2004-01-07 2010-10-10 Чирон Корпорейшн Не мышиное анти-m-csf-антитело (варианты), его получение и использование
SI2177537T1 (sl) * 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
US7875598B2 (en) * 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
EP2275445A3 (en) 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2005291486A1 (en) * 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1841455A1 (en) * 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
US20090053229A1 (en) * 2005-05-12 2009-02-26 Lee Daniel H S Methods of Treating Conditions Involving Neuronal Degeneration
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
EP2311876A3 (en) * 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
US20080233118A1 (en) * 2005-07-28 2008-09-25 Novartis Ag Uses Of Antibody To M-Csf
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2633756C (en) * 2005-12-21 2015-11-24 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
NZ569204A (en) * 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
TWI392684B (zh) * 2006-04-05 2013-04-11 Abbott Biotech Ltd 抗體之純化
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
CA2649538C (en) * 2006-04-21 2014-06-03 Yatin Gokarn Buffering agents for biopharmaceutical formulations
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
JP5406027B2 (ja) * 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
KR20140033241A (ko) 2006-08-18 2014-03-17 노바르티스 아게 Ｐｒｌｒ 특이적 항체 및 그 용도
JP5775260B2 (ja) 2006-09-06 2015-09-09 シー３ ジアン インコーポレイテッド 選択的に標的化された抗菌性ペプチドおよびその使用
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
WO2008033333A2 (en) 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
SI2081595T1 (sl) 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
JP5631591B2 (ja) * 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
WO2008052796A1 (en) 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
AU2007329307B2 (en) 2006-12-07 2012-08-02 Novartis Ag Antagonist antibodies against EphB3
CN103405768A (zh) 2006-12-20 2013-11-27 爱克索马技术有限公司 用于治疗IL-1β相关疾病的方法
WO2008079290A2 (en) * 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
AU2008214386B2 (en) * 2007-02-02 2013-09-19 Amgen Inc Hepcidin and hepcidin antibodies
MX2009008178A (es) 2007-02-02 2009-10-26 Biogen Idec Inc Uso de semaforina 6a para promover la mielinizacion y la diferenciacion de oligodendrocitos.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
ES2556214T3 (es) 2007-11-12 2016-01-14 U3 Pharma Gmbh Anticuerpos para AXL
CN101945893B (zh) 2007-12-14 2015-02-25 诺沃-诺迪斯克有限公司 抗人nkg2d抗体及其用途
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
JP6078217B2 (ja) 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
EP2408816B1 (en) 2009-03-20 2019-09-04 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
MX347291B (es) 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
CA2767063A1 (en) 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means
EP2287336A1 (fr) 2009-07-31 2011-02-23 Exhonit Therapeutics SA Procédés et méthodes de diagnostic de la maladie d'Alzheimer
US20120231013A1 (en) 2009-07-31 2012-09-13 Black Roy A Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
EP2308897A1 (en) 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
TW201129379A (en) 2009-11-20 2011-09-01 Amgen Inc Anti-Orai1 antigen binding proteins and uses thereof
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2371863A1 (en) 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
EP2569430B1 (en) 2010-05-12 2018-10-17 The Trustees of Columbia University in the City of New York Methods for producing enteroendocrine cells that make and secrete insulin
US8735548B2 (en) 2010-06-30 2014-05-27 Amgen Inc. Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
US20140072983A1 (en) 2010-08-10 2014-03-13 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
CN105440134A (zh) 2010-08-16 2016-03-30 安姆根公司 结合肌肉生长抑制素的抗体、组合物和方法
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
CN103180342A (zh) 2010-10-27 2013-06-26 皮埃尔法布雷医药公司 用于治疗hiv的抗体
KR20140009311A (ko) 2011-01-18 2014-01-22 암젠 인크 Nav1.7 넉아웃 마우스 및 이의 용도
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
PT2714735T (pt) 2011-06-03 2021-10-26 Xoma Technology Ltd Anticorpos específicos para tgf-beta
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
ES2693508T3 (es) 2011-10-26 2018-12-12 Amgen Inc. Métodos para reducir o eliminar la modificación y la degradación de proteínas debidas a una exposición a luz UV
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
WO2013126813A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
WO2013149219A2 (en) 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
AU2013266069B2 (en) 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
CA2874936A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Vaccine
CA2877573A1 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
EP2864358B1 (en) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014022102A1 (en) 2012-08-01 2014-02-06 Amgen Inc. Methods of using anti-apoptotic compounds to modulate one or more properties of a cell culture
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
AR093357A1 (es) 2012-11-05 2015-06-03 Pf Medicament Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
FR3004184B1 (fr) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech Anticorps anti-gluten desamide et utilisations.
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2014244444A1 (en) 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
CN111518199A (zh) * 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
JP6820743B2 (ja) 2013-09-05 2021-01-27 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US20160216262A1 (en) 2013-09-12 2016-07-28 Institut National De La Sante Et De La Recherche Medicale Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
MX2016005572A (es) 2013-10-31 2016-12-09 Amgen Inc Uso de monensina para regular la glicosilacion de proteinas recombinantes.
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
IL282517B (en) 2014-01-29 2022-07-01 Amgen Inc Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
CN106459204B (zh) 2014-04-25 2021-02-02 皮埃尔法布雷医药公司 Igf-1r抗体及其作为定位载体用于治疗癌症的用途
AU2015250759B2 (en) 2014-04-25 2017-11-30 Pierre Fabre Medicament IGF-1R antibody-drug-conjugate and its use for the treatment of cancer
EP3607996B1 (en) 2014-04-25 2023-01-04 Pierre Fabre Medicament Antibody-drug-conjugate and its use for the treatment of cancer
US10487314B2 (en) 2014-06-26 2019-11-26 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
ES2962385T3 (es) 2014-10-15 2024-03-18 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
AU2015331602A1 (en) 2014-10-17 2017-04-27 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
EP3034620A1 (en) 2014-12-17 2016-06-22 Diaxonhit Compositions and methods for diagnosing thyroid cancer
FR3030758A1 (fr) 2014-12-19 2016-06-24 Inst Nat De La Rech Agronomique (Inra) Marqueurs diagnostiques de la maladie de crohn
WO2016126611A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
WO2016130898A2 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
KR102511343B1 (ko) 2015-03-05 2023-03-17 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체
WO2016156557A1 (en) 2015-04-03 2016-10-06 Alienor Farma Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
EP3280443B1 (en) 2015-04-08 2022-08-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
JP2018515603A (ja) 2015-05-04 2018-06-14 ビオノル・イムノ・アクシェセルスカプＢｉｏｎｏｒ Ｉｍｍｕｎｏ ＡＳ Ｈｉｖワクチン用の投薬レジメン
FR3036287A1 (fr) 2015-05-19 2016-11-25 Univ Bordeaux Traitement et detection des trypanosomes
WO2017024285A2 (en) 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
AU2016332900C1 (en) 2015-09-29 2024-02-01 Amgen Inc. ASGR inhibitors
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
RU2728568C2 (ru) 2015-10-26 2020-07-30 Пьер Фабр Медикамент Композиция для лечения рака, экспрессирующего igf-1r
US10849906B2 (en) 2015-11-30 2020-12-01 Yanhui Xie Use of Akt2 in diagnosis and treatment of tumor
CN108780091A (zh) 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
CA3193481A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating esophageal cancer
CN108700588A (zh) 2015-12-31 2018-10-23 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗胃癌的组合物和方法
KR20190026642A (ko) 2016-01-29 2019-03-13 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017153432A1 (en) 2016-03-07 2017-09-14 Pierre Fabre Medicament A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
ES2914118T3 (es) 2016-05-11 2022-06-07 Amgen Inc Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa
SG11201900138TA (en) 2016-07-07 2019-02-27 Iovance Biotherapeutics Inc Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
CN109803680B (zh) 2016-08-01 2024-05-17 佐马美国有限公司 甲状旁腺激素受体1(pth1r)抗体和其用途
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
RU2019123613A (ru) 2017-01-03 2021-02-05 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9
US20190367611A1 (en) 2017-02-01 2019-12-05 CentryMed Pharmaceutical Inc. Monomeric human igg1 fc and bispecific antibodies
ES2925227T3 (es) 2017-03-30 2022-10-14 Ecs Progastrin Sa Composiciones y procedimientos para detectar el cáncer de pulmón
KR102351556B1 (ko) 2017-03-30 2022-01-14 프로가스트린 에 캔서스 에스.에이 알.엘. 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
EP3398967A1 (en) 2017-05-04 2018-11-07 B Cell Design Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
AU2018300189A1 (en) 2017-07-14 2020-01-30 Pfizer, Inc. Antibodies to MAdCAM
EP3444272A1 (en) 2017-08-17 2019-02-20 International-Drug-Development-Biotech Treatment of ck8 positive cancers in relation with k-ras gene status
WO2019046600A1 (en) 2017-08-30 2019-03-07 Amgen Inc. INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE
KR102461238B1 (ko) 2017-12-05 2022-11-01 프로가스트린 에 캔서스 에스.에이 알.엘. 암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
CN112424228A (zh) 2018-07-04 2021-02-26 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
KR20210065991A (ko) 2018-09-27 2021-06-04 피에르 파브르 메디카먼트 설포말레이미드계 링커 및 상응하는 컨쥬게이트
US20220048966A1 (en) 2018-09-28 2022-02-17 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
KR20210105890A (ko) 2018-12-17 2021-08-27 레비토프 리미티드 트윈 면역 세포 인게이저
EP3962941A4 (en) 2019-04-30 2023-05-10 Gigagen, Inc. RECOMBINANT POLYCLONAL PROTEINS AND METHODS OF USE THEREOF
US20200362057A1 (en) 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
MX2021015045A (es) 2019-06-07 2022-03-17 Amgen Inc Construcciones de unión biespecíficas.
JP2022538075A (ja) 2019-06-26 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体結合ｃｅａ及び４－１ｂｂｌの融合
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
TW202134280A (zh) 2019-12-05 2021-09-16 美商索倫多醫療公司 包含抗cd47抗體與腫瘤靶向抗體之組合物及方法
AU2021214795A1 (en) 2020-01-31 2022-08-18 The Cleveland Clinic Foundation Anti-Müllerian Hormone Receptor 2 antibodies and methods of use
CN115485300A (zh) 2020-02-26 2022-12-16 索伦托药业有限公司 具有通用掩蔽部分的可活化的抗原结合蛋白
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
EP3889183A1 (en) 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
WO2021217083A1 (en) 2020-04-24 2021-10-28 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
EP4139681A2 (en) 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Lateral flow device for detection of neutralizing antibodies against sars-cov-2
US20230203198A1 (en) 2020-06-04 2023-06-29 Amgen Inc. Bispecific binding constructs
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
JP2023532279A (ja) 2020-06-26 2023-07-27 ソレント・セラピューティクス・インコーポレイテッド 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
CN116209677A (zh) 2020-06-26 2023-06-02 索伦托药业有限公司 抗pd1抗体及其用途
JP2023533533A (ja) 2020-07-10 2023-08-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
CN117280211A (zh) 2020-11-04 2023-12-22 索伦托药业有限公司 用于冠状病毒感染的高灵敏度检测的侧向流动装置及其制造和使用方法
CN116783217A (zh) 2020-12-03 2023-09-19 安进公司 具有多个结合结构域的免疫球蛋白构建体
CR20230385A (es) 2021-01-12 2023-09-25 F Hoffmann La Roche Ag [ Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células
EP4277668A1 (en) 2021-01-13 2023-11-22 F. Hoffmann-La Roche AG Combination therapy
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4301418A1 (en) 2021-03-03 2024-01-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
US20240166731A1 (en) 2021-03-26 2024-05-23 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
AU2022290563A1 (en) 2021-06-09 2024-01-25 Vivasor, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
TW202328442A (zh) 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
WO2023154305A2 (en) 2022-02-10 2023-08-17 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
TW202346355A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
TW202400636A (zh) 2022-03-11 2024-01-01 比利時商健生藥品公司 多特異性抗體及其用途(一)
WO2023170295A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
GB8800078D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2656544B1 (fr) 1989-12-29 1994-02-25 Diffusion Materiels Fluides Sa Procede et unite de separation par microfiltration tangentielle, osmose inverse ou ultrafiltration a deux etages.

Also Published As

Publication number Publication date
AU8200591A (en) 1992-02-04
CA2065325C (en) 2002-09-24
EP0491031A1 (en) 1992-06-24
EP0491031B1 (en) 1996-05-01
GB2251859A (en) 1992-07-22
CA2065325A1 (en) 1992-01-06
GB2251859B (en) 1995-01-11
AU651984B2 (en) 1994-08-11
GB9014932D0 (en) 1990-08-22
JPH05502587A (ja) 1993-05-13
DE69119211D1 (de) 1996-06-05
US5877293A (en) 1999-03-02
WO1992001059A1 (en) 1992-01-23
DE69119211T2 (de) 1996-12-19
GB9204803D0 (en) 1992-04-29
ATE137534T1 (de) 1996-05-15

Similar Documents

Publication Publication Date Title
KR920702425A (ko) Cdr 이식된 항-cea 항체 및 그의 제조
Gonzales et al. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity
US8404817B2 (en) Humanized anti-prostate stem cell antigen monoclonal antibody
Neumaier et al. Cloning of the genes for T84. 66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84. 66 genes in myeloma and Chinese hamster ovary cells
Kashmiri et al. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49
US6676924B2 (en) CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
CN101134779B (zh) 人cd22特异性抗体及其治疗和诊断应用
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
US7273608B2 (en) Humanized anti-CEA T84.66 antibody and uses thereof
EP1442061B1 (en) Reducing immunogenicities of immunoglobulins by framework-patching
ES2277341T3 (es) Anticuerpo bioespecifico para tratar el linfoma de linfocitos b y linea celular.
CA2153692A1 (en) Recombinant anti-vla4 antibody molecules
Jolliffe Humanized antibodies: enhancing therapeutic utility through antibody engineering
JP2006506955A5 (ko)
RU2009107494A (ru) АНТИТЕЛА К ErbB2
RU2004127458A (ru) Анти-cd20 антитела, их гибридные белки и способы их использования
JP2008509656A (ja) Ｔａｇ−７２に対するヒト化モノクローナル抗体
CA2420231A1 (en) Antibodies to human il-1.beta.
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
Roque-Navarro et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method
CA2223491A1 (en) Cdr-grafted anti-tissue factor antibodies and methods of use thereof
CA2441845A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
Buchegger et al. Selective tumor localization of radiolabeled anti‐human melanoma monoclonal antibody fragment demonstrated in the nude mouse model
WO2008081331A2 (en) Enhancing the level of antibody expression by framework re-engineering
AU666029B2 (en) Granulocyte-binding antibody fragments, their preparation and use

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid